Who are Solu's investors?

Solu's investors include Astellas Venture Management LLC, Longwood Fund, Pappas Capital.

Solu

21 employees on LinkedIn · 3 known investors

Find your way into Solu

1,680 people in our graph share verified history with the Solu team — schools, employers, funds. One of them is your warm intro.

Noubar Afeyanunlockedknows John Pribis · together at Apriori Bio (overlapped)

knows the team · via USA Triathlon

knows the team · via DEM Biopharma, Inc.

knows the team · via Celsius Therapeutics

×2knows the team · via Longwoodfund

×3knows the team · via Longwood Fund

Solu Therapeutics is a clinical-stage biotech developing a class of antibody therapeutics that link bifunctional small molecules to proprietary effector antibodies (its CyTAC and TicTAC platforms) to reach cell surface targets like GPCRs and ion channels. Its pipeline targets oncology, immunology and inflammation, and pain, with a lead program in Phase 1 trials for chronic myelomonocytic leukemia.

Biotech Healthtech

Founders & leadership

Phil VickersCEO / Leadership

Michael Boretti LeadershipMichael Boretti has over 15 years of experience in biotech, with expertise in corporate strategy, business development, and operations across discovery through clinical-stage companies. He leads Solu Therapeutics, which is developing bifunctional antibody therapeutics targeting GPCRs, ion channels, and other cell surface proteins for oncology, immunology, and pain indications.

Brandon Turunen LeadershipBrandon Turunen is Chief Scientific Officer of Solu Therapeutics, a clinical-stage biotech company developing bifunctional antibody therapeutics targeting oncology, immunology, and inflammation. He has led multidisciplinary drug discovery teams and advanced first-in-class programs through translational development and into clinical trials.

Sergio SantillanaLeadership

Enda Moran LeadershipEnda Moran is a healthcare executive with experience in biologics, vaccine development, and commercialization across pharma and biotech, and has led global teams on drug development initiatives.

Kelly HonohanLeadership

Marissa Timothy LeadershipMarissa Timothy is a clinical operations leader with experience overseeing trials across Phase I-IV oncology and immunology programs at biotech and pharmaceutical companies, with expertise in site selection, vendor management, and FDA compliance.

John Pribis LeadershipJohn Pribis is a leader at Solu Therapeutics, a clinical-stage biotech company developing bifunctional antibody therapeutics targeting oncology, immunology, inflammation, and pain.

Investors · 3

Astellas Venture Management LLClisted by Astellas Venture Management LLCSouth San Francisco · $200K – $5M

Longwood Fundlisted by Longwood FundBoston

How we know: Longwood Fund's portfolio page · the VCSheet dataset · Not right? Tell us

Pappas CapitalreportedResearch Triangle Park · $100K – $6M

How we know: funding news · Not right? Tell us

Funding

SEC filings, press & company announcements

Undisclosed amountSeries AApr 2025
Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

Frequently asked questions

What does Solu do?: Solu Therapeutics is a clinical-stage biotech developing a class of antibody therapeutics that link bifunctional small molecules to proprietary effector antibodies (its CyTAC and TicTAC platforms) to reach cell surface targets like GPCRs and ion channels. Its pipeline targets oncology, immunology and inflammation, and pain, with a lead program in Phase 1 trials for chronic myelomonocytic leukemia.
Who are Solu's investors?: Solu's investors include Astellas Venture Management LLC, Longwood Fund, Pappas Capital.